Soleno Therapeutics Faces Class Action Lawsuit Following Disappointing DCCR Launch and Share Price Plummet

Legal Troubles for Soleno Therapeutics

In a recent development reflecting ongoing challenges in the biotech sector, Soleno Therapeutics, Inc. has found itself embroiled in a securities class action lawsuit filed on April 3, 2026 by the law firm Hagens Berman. This lawsuit targets investors who acquired Soleno's common stock during a specified period, from March 26, 2025, to November 4, 2025, and follows a significant downturn in the company's share price linked to disappointing findings related to its drug, DCCR (marketed as VYKAT™ XR).

The Context of the Lawsuit

This legal action is rooted in Soleno’s report on November 5, 2025, detailing the underwhelming performance of DCCR, a medication designed to treat hyperphagia, regarded as a severe symptom of Prader-Willi Syndrome (PWS). The report disclosed that the product might not meet operational expectations, sparking a dramatic 26% drop in the company’s stock value on the same day.

Allegations of Investor Misrepresentation

The lawsuit claims that Soleno's management misrepresented critical facts about DCCR’s safety and efficacy. Prior statements from the company had suggested a positive trajectory in the product's launch, with executives asserting that performance exceeded expectations. Legal representatives now scrutinize these assurances, claiming they obscured genuine safety concerns associated with DCCR, particularly regarding fluid retention observed in clinical trials.

Investors had been led to believe that DCCR’s introduction to the market would be straightforward and successful. However, evidence suggests that there were substantial risks and lower commercial viability than Soleno disclosed. A notable shift in investor confidence occurred on August 15, 2025, when activist group Scorpion Capital raised alarms over potential safety issues, particularly after receiving reports of children requiring hospitalization due to adverse reactions following DCCR usage.

Market Reactions and Continued Investigations

Following the revelations from Scorpion Capital and ensuing media reports, the corporate image of Soleno began to tarnish as share prices plummeted nearly 40% from their previous highs. That's when Hagens Berman initiated an investigation to ascertain whether Soleno violated federal securities laws, prompting them to reach out to affected investors for assistance in collecting information about their financial losses.

Reed Kathrein, a partner at the firm spearheading the investigation, emphasized their commitment to investigating potential deception around the commercial potential of DCCR. Legal experts and analysts are now closely monitoring any fallout from this lawsuit that could further affect Soleno's stock and stakeholder confidence.

Whistleblower Program and Further Steps

For those with non-public information regarding Soleno, the legal team encourages potential whistleblowers to come forward, noting that the SEC Whistleblower program can offer compensation of up to 30% of sanctions collected from any successful recovery. This underscores the legal avenues available to those looking to contribute information related to the case.

As the lawsuit unfolds, shareholders and interested parties will be watching the developments closely, assessing the wider implications for other biotech firms navigating similar challenges in product development and investor communications. With stakes high, both legal and financial ramifications are likely to reverberate across the industry as Soleno grapples with its internal challenges while seeking to restore investor confidence and re-establish market credibility.